All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
European Commission approves glofitamab in combination with gemcitabine and oxaliplatin for the treatment of adult patients with R/R DLBCL
Bookmark this article
On April 14, 2025, the European Commission granted approval to glofitamab (Glofit), a CD20×CD3 T-cell-engaging bispecific antibody, in combination with gemcitabine and oxaliplatin (GemOx), for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified who are ineligible for autologous stem cell transplant.1 This announcement is based on key results from the pivotal phase III STARGLO trial (NCT04408638).1
STARGLO trial
STARGLO is a phase III, multicenter, open-label, randomized trial evaluating the efficacy and safety of Glofit-GemOx vs rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory DLBCL who have received ≥1 prior line of therapy and who are not candidates for autologous stem cell transplant or who have received ≥2 prior lines of therapy.1 Among the evaluable patients with DLBCL (N = 274)2:
-
In the primary analysis, at a median follow-up of 11.3 months, overall survival was longer for Glofit-GemOx vs R-GemOx (hazard ratio, 0.59; 95% confidence interval, 0.40–0.89; p = 0.011).
-
In an updated analysis, at a median follow-up of 20.1 months, the median overall survival (25.5 months vs 12.9 months; p = 0.0064) and median progression-free survival (13.8 months vs 3.6 months; p < 0.0001) were higher for Glofit-GemOx vs R-GemOx.
-
Safety of Glofit-GemOx was consistent with the known safety profiles of the individual agents. Cytokine release syndrome occurred in 44% of patients in the Glofit-GemOx group, and was mostly low grade (Grade 1, 31%; Grade 2, 10%; and Grade 3, 2%).
- GlobeNewswire. European Commission approves Roche’s Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy. https://www.globenewswire.com/news-release/2025/04/14/3060614/0/en/European-Commission-approves-Roche-s-Columvi-as-the-first-bispecific-antibody-for-diffuse-large-B-cell-lymphoma-after-initial-therapy.html. Published Apr 14, 2025. Accessed Apr 14, 2025.
- Abramson JS, Ku M, Hertzberg M, et al. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. Lancet. 2024;404(10466):1940-1954. DOI: 10.1016/S0140-6736(24)01774-4
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youRelated articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox